Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Texas
-
San Antonio, Texas, United States, 78215
- Texas Liver Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women not of childbearing potential (WNOCBP) and males. Women must have documented proof they are not of childbearing potential
- BMI of 20.0 to 38.0 kg/m2, inclusive
- Hepatic subjects classified as Child-Pugh mild (Class A) or Child-Pugh moderate (Class B) who have had no significant change to disease status in past 6 months and are on stable treatment regimen
- Healthy subjects must not have clinically significant deviations from normal in medical history, physical exam, ECGs, vital signs or clinical lab values
Exclusion Criteria:
- Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation
- Use of corticosteroids, nonsteroidal anti-inflammatory compounds, aspirin or other antiplatelet agents or anticoagulants within 2 weeks of dosing
- Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse within the last 6 months
- Subjects must not have a current or recent (within 3 months) GI disease that increases participant risk of GI bleeding or interferes with absorption of the study drug
Other protocol defined inclusion and exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Mild Hepatic Subjects
Subjects are given a single dose of BMS-986177
|
Single oral dose
|
|
EXPERIMENTAL: Moderate Hepatic Subjects
Subjects are given a single dose of BMS-986177
|
Single oral dose
|
|
EXPERIMENTAL: Healthy Match Subjects
Subjects are given a single dose of BMS-986177
|
Single oral dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum observed plasma concentration (Cmax) of BMS-986177
Time Frame: Up to 5 days
|
Up to 5 days
|
|
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-987177
Time Frame: Up to 5 days
|
Up to 5 days
|
|
Area under the plasma concentration-time curve from time zero to the time the last quantifiable concentration (AUC(0-T)) of BMS-986177
Time Frame: Up to 5 days
|
Up to 5 days
|
|
Area under the plasma concentration-time curve from time zero to (AUC(0-72)) of BMS-986177
Time Frame: Up to 5 days
|
Up to 5 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation
Time Frame: Screening until 30 days after discontinuation of dosing or subject's participation
|
Screening until 30 days after discontinuation of dosing or subject's participation
|
|
Number of participants with clinical laboratory abnormalities
Time Frame: Screening until 30 days after discontinuation of dosing or subject's participation
|
Screening until 30 days after discontinuation of dosing or subject's participation
|
|
Number of participants with clinically significant changes in electrical activity of the heart measured by electrocardiogram (ECG)
Time Frame: Screening until 30 days after discontinuation of dosing or subject's participation
|
Screening until 30 days after discontinuation of dosing or subject's participation
|
|
Number of participants with vital sign abnormalities
Time Frame: Screening until 30 days after discontinuation of dosing or subject's participation
|
Screening until 30 days after discontinuation of dosing or subject's participation
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CV010-013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.